GLP-1 weight loss and kidney disease
What the evidence says about GLP-1 treatment when kidney function is reduced, how eGFR and creatinine are interpreted during weight loss, and the monitoring that keeps treatment safe.
Written by Professor Mohammed Mahdi Althaf
Medically reviewed by Professor Mohammed Mahdi Althaf, Consultant Nephrologist · 1 August 2026
Overview
Weight reduction in chronic kidney disease (CKD) can reduce proteinuria and cardiovascular risk, but treatment requires closer monitoring than in the general population. Data from the FLOW trial and recent KDIGO updates highlight the potential for kidney protection alongside weight loss.
KDIGO and UKKA Clinical Consensus
- Recent KDIGO (Kidney Disease: Improving Global Outcomes) 2024 Clinical Practice Guidelines and UK Kidney Association (UKKA) position statements support the use of GLP-1 receptor agonists in patients with CKD and Type 2 Diabetes for their cardiorenal benefits.
- Use in patients with CKD but without diabetes is increasingly supported by clinical trial data (such as the FLOW and STEP-HFpEF trials) for obesity management and slowing progression.
- Standard nephrology practice involves starting at the lowest possible dose to minimise gastrointestinal-related fluid loss, as per ABCD-UKKA joint guidance.
Why creatinine is tracked
Gastrointestinal side effects (nausea/vomiting) can cause dehydration, which may transiently reduce kidney function (Acute Kidney Injury or AKI). Serial creatinine readings allow Professor Mohammed Mahdi Althaf to distinguish a reversible dip from genuine disease progression, following Renal Association monitoring standards.
"Beyond the Injection" — Holistic Management
Obesity management in CKD involves more than just suppression of appetite. It requires:
- Managing sarcopenia (muscle loss) which is common in CKD and exacerbated by rapid weight loss.
- Ensuring adequate protein intake (guided by CKD stage and Association for the Study of Obesity guidance on preserving lean mass).
- Monitoring for "dry weight" changes in those on dialysis.
Preparing for your appointment
Can GLP-1s actually help my kidneys?
Yes. Clinical trials indicate they can slow the rate of GFR decline and significantly reduce the risk of kidney failure and cardiovascular death in high-risk patients.
What if my GFR is very low?
Usage is still possible but requires expert nephrology supervision, which is why KidneyWeight Clinic specialises in this high-risk group.
References
- KDIGO 2024 Clinical Practice Guideline for the Management of Chronic Kidney Disease
- UK Kidney Association (UKKA) Obesity and CKD Statement
- ABCD-UKKA Joint Guidelines: Management of CKD in Type 2 Diabetes
- The FLOW Trial: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and CKD
- Association for the Study of Obesity (ASO) - Obesity Management Clinical Standards
This article is general patient information reviewed by a consultant nephrologist. It is not individual medical advice; treatment decisions are made at a face-to-face consultation.